Physician profile
Robert James Leach
NPI 1114910411
$4,098.69
in general payments reported to CMS, 2019-2025
24 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $506 · 2020: $472 · 2021: $167 · 2022: $561 · 2023: $786 · 2024: $782 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,357 · Education: $35.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.13 |
| Education | $35.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $765.39 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $456.33 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $347.39 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $304.45 | 2022-2025 | Tarpeyo |
| Fresenius USA Marketing, INC. | $293.68 | 2019-2025 | Velphoro, Velphoro |
| Bayer Healthcare Pharmaceuticals INC. | $271.90 | 2022-2025 | |
| Amgen INC. | $251.90 | 2022-2025 | Tavneos, Aranesp, Parsabiv |
| Ardelyx, INC. | $231.61 | 2024-2025 | Ibsrela |
| Vifor Pharma, INC. | $205.91 | 2021-2023 | Veltassa |
| Aurinia Pharma U.S., INC. | $173.44 | 2021-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $117.74 | 2022-2025 | Jesduvroq, Benlysta |
| Otsuka America Pharmaceutical, INC. | $110.70 | 2019-2023 | Jynarque |
| Novartis Pharmaceuticals Corporation | $106.97 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $77.75 | 2020 | |
| Travere Therapeutics, INC. | $67.00 | 2023-2025 | Filspari |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $63.94 | 2023 | Acthar |
| Novo Nordisk INC | $50.83 | 2025 | Ozempic, Rybelsus |
| Amag Pharmaceuticals, INC. | $39.69 | 2022 | |
| Baxter Healthcare | $38.04 | 2022 | |
| Opko Pharmaceuticals, LLC | $31.98 | 2023-2024 | Rayaldee |
| Horizon Therapeutics Plc | $28.65 | 2023 | Krystexxa |
| Kyowa Kirin, INC. | $24.97 | 2023 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $20.22 | 2023 | |
| Harmony Biosciences LLC | $18.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Leach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.